Current Health offers a wearable digital device that captures a patient’s vital signs and allows carers and health professionals to monitor oxygen saturation, pulse rates and respiration, whether the patient is at home or in the treating medical facility. The technology is currently in use by healthcare providers in the UK and the US, and the firm itself has also secured three FDA 501(k) clearances for the platform.
With the latest funding – which follows a seeding round of over £6 million in the past year – the company plans further international and domestic growth, particularly the opening of headquarters in New York, as well as further expansion of the team.
“We’ve spent the past three years quietly and carefully building and testing our platform directly with healthcare providers. Now, with our platform FDA-cleared and through partnerships with some of the biggest healthcare providers and pharmaceutical companies in the world, we plan to scale our solution to better treat millions of lives over the next five years,” said Current Health CEO Christopher McCann. “By helping healthcare providers treat patients preventatively and at the earliest point, we can play a key role in enabling sustainable, high-quality and universal healthcare delivery.”